PRO MEDICUS LIMITED — Interim / Quarterly Report 2017

Feb 16, 2017

Appendix 4D Half-Year Report

Rule 4.2A

==> picture [113 x 30] intentionally omitted <==

Appendix 4D

Half-Year Report

1. Company details

Name of entity

1. Company details Name of entity	1. Company details Name of entity	1. Company details Name of entity
Pro Medicus Limited
ABN or equivalent company reference 25 006 194 752	Financial half year ended (‘current period’) 31 December 2016	Financial half year ended (‘previous period’)
25 006 194 752	31 December 2016	31 December 2015

2. Results for announcement to the market.

The information in this report should be read in conjunction with the 30 June 2016 Annual Financial Report.

ASX Listing Rules **Ref **		2016 A$’000	2015 A$’000	2015 A$’000	% change
2.1	Revenue from ordinary activities	15,202	14,285		6.4%
2.2	Underlying Profit before Tax (minus one- offs and currency gains) One-offs (Employee entitlements, redundancy costs, legal) Currency gains Profit for the period from continuing operations before tax Profit/(Loss) from ordinary activities after tax attributable to members	5,877 - 1,032 6,909 4,796	5,063 (754) 171 4,480 2,941		16.1% N/A 503.5% 54.2% 63.1%
2.3	Net Profit/(Loss) for the period attributable to members % change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.		4,796 Up 63.1%
2.4	Dividends (distributions)	Amount per security		Unfranked amount persecurity
	Unfranked dividend amount per security Final Dividend Previous corresponding period Interim Dividend Previous corresponding period	1.5 cents 1.0 cents 1.5 cents 1.5 cents		1.5 cents 1.0 cents 1.5 cents 1.5 cents

Page 1

Appendix 4D Half-Year Report

==> picture [113 x 30] intentionally omitted <==

		Appendix 4D Half-Year Report
	2.5	Record date for Interim dividend 10 March 2017 Interim dividends payment dates 24 March 2017
	2.6	REVIEW AND RESULTS OF OPERATIONS The Company reported a first half after tax profit of $4.80m, an increase of $1.86m (up 63.1%) compared to the same period last year. Revenue for the 6 month period of the Company increased from $14.28m to $15.20m, an increase of 6.4%. The result from the underlying operations for the period was a profit of $4.08m compared to an underlying profit of $2.82m from the previous corresponding period, an increase of 44.7% (The underlying profit is made up of reported profit after-tax of $4.80m and subtracting the after-tax net currency gain of $0.72m (Dec 2015: $0.12m)). During the period the Company continued to make strong inroads into the North America market winning a $18.0m contract with Mayo Clinic, one the most recognised health systems in North America as well as globally. The Company made significant progress with its installations with all key implementations being on or ahead of schedule. The Company is looking to further build on its presence in North America and is actively pursuing key opportunities both within the enterprise imaging/large teaching hospital and private imaging centre markets. The Company’s European business performed in line with expectations. A capital sale of $1.5m in the previous corresponding period was not repeated in the current half. The company’s Australian business improved as a result of increased adoption of the Visage RIS and Visage PACS products. Promedicus.net, the company's e-health offering, continuing to perform well throughout the period despite increasing competition. The Company continued its significant investment in R&D, both in Australia as well as overseas. The company's cash reserves have increased by $3.17m for the 6 month period with cash reserves of $20.28m at the end of December 2016. The company remains debt free. The Board is of the view that there are sufficient cash reserves to fund the anticipated growth of the business from internal sources. As a result the company has announced anunfrankedinterimdividend of 1.5c pershare.
	3.	Net Tangible Assets per security 2016 2015 Net Tangible Assets per security $0.21 $0.16
	4.	Details of entities over which control has been gained or lost during the period There are no entities over which control has been gained or lost during the period.

Page 2

Appendix 4D Half-Year Report

==> picture [113 x 30] intentionally omitted <==

	5.	Details of Dividends
		Interim Dividend An unfranked Interim Dividend of 1.5 cents (2015: 1.5 cents) per share will be paid on 24 March 2017.	2016 $’000	2015 $’000
			1,540	1,526
	6.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.
	7.	Associates and joint venture entities There are no associates or relevant joint ventures.
	8.	Foreign Entity accounting standards Not applicable
	9.	Audit Statement This report is based on accounts to which one of the following applies. (Tick one)  The +accounts have been audited.  The+accounts have been subject to review.  The +accounts are in the process of being audited or subject to review.  The+accounts have_not_ yet been audited or reviewed.

Sign here:

==> picture [99 x 70] intentionally omitted <==

Peter T Kempen Chairman

Date: 17[th] February 2017

Page 3